GlassScriptPhysician profile
Ashwini Gandhe
NPI 1447278395
$11,955.63
in general payments reported to CMS, 2019-2025
57 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,740 · 2020: $1,282 · 2021: $1,817 · 2022: $1,608 · 2023: $1,612 · 2024: $1,737 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,509.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,827.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,777.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,349.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $614.08 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $611.90 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Lilly USA, LLC | $583.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $471.93 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $454.49 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $355.12 | 2019-2024 | Xarelto, Spravato |
| Astellas Pharma US INC | $344.02 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $291.00 | 2019-2023 | Verquvo, Gardasil 9, Pneumovax 23 |
| Horizon Therapeutics Plc | $209.14 | 2019-2022 | |
| Abbott Laboratories | $188.24 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $178.01 | 2019-2025 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.40 | 2020-2024 | Xifaxan, Trulance |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwini Gandhe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.